

PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 004974.01078	APPLICATION NUMBER: 10/509,715
	APPLICANT Golz <i>et al.</i>	
	FILING DATE March 4, 2005	GROUP ART UNIT 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/SHS/		Levy, "Myocardial 15-Epi-lipoxin A ₄ Generation Provides a New Mechanism for the Immunomodulatory Effects of Statins and Thiazolidinediones," <i>Circulation</i> 114, 873-75, 2006.
↓		Rogers <i>et al.</i> , "Lipoxin A ₄ Modifies Platelet-Derived Growth Factor-Induced Profibrotic Gene Expression in Human Renal Mesangial Cells," <i>Am. J. Pathol.</i> 167, 683-94, September 2005
		Wu <i>et al.</i> , "Lipoxin A ₄ Inhibits Proliferation of Human Lung Fibroblasts Induced by Connective Tissue Growth Factor," <i>Amer. J. Respiratory Cell and Molecular Biology</i> 34, 65-72, 2006
		(no author), BLAST search of SEQ ID NO:2, pages 1-50, May 10, 2007
		(no author), GenBank Accession No. NP_001453, pages 1-4, May 10, 2007

EXAMINER Shulamith H. Shafer <small>Digitally signed by Shulamith H. Shafer DN: cn=Shulamith H. Shafer, o=US, ou=USPTO, ou=AAU 1647, email=shulamith.shafer@uspto.gov Date: 2007.07.13 10:30:58 -0400</small>	DATE CONSIDERED 07/13/2007
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	